Dr. Geynisman on Sequencing of Agents for Kidney Cancer

Daniel M. Geynisman, MD
Published: Tuesday, Oct 03, 2017



Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Currently, tyrosine kinase inhibitors (TKIs) are given first, followed by drugs such as nivolumab (Opdivo), cabozantinib (Cabometyx), and lenvatinib (Lenvima) plus everolimus (Afinitor), states Geynisman.

Every patient is unique and has different needs and comorbidities. There are a number of options so determining treatment depends on the patient.


Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Currently, tyrosine kinase inhibitors (TKIs) are given first, followed by drugs such as nivolumab (Opdivo), cabozantinib (Cabometyx), and lenvatinib (Lenvima) plus everolimus (Afinitor), states Geynisman.

Every patient is unique and has different needs and comorbidities. There are a number of options so determining treatment depends on the patient.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x